KATHLEEN BUI: Open Payments
NPI 1801539697 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,030 in 50 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $564 · 2025 $1,030
Food & beverage: $1,030
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $339 |
| Janssen Biotech, Inc. | 5 | $184 |
| Madrigal Pharmaceuticals | 9 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $94 |
| GENZYME CORPORATION | 2 | $55 |
| Lilly USA, LLC | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Braintree Laboratories, Inc. | 1 | $22 |
Products named: RINVOQ, TREMFYA, REZDIFFRA, EOHILIA, DUPIXENT, SKYRIZI, LINZESS, OMVOH.
Industry payments across TX — which companies pay providers there.
